| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Precision BioSciences, Inc.
13G/A
Amendment 2
DTIL · 74019P207
|
3.7% |
8/6/2025
Event 6/30/2025
|
|||
| Novartis Pharma AG | 3.7% | ||||
| Novartis AG | 3.7% | ||||
|
Erasca, Inc.
13G/A
Amendment 1
ERAS · 29479A108
|
4.4% |
2/12/2025
Event 12/31/2024
|
|||
| Novartis Pharma AG | 4.4% | ||||
| Novartis AG | 4.4% | ||||
|
Precision BioSciences, Inc.
13G/A
Amendment 1
DTIL · 74019P207
|
5.4% |
2/12/2025
Event 12/31/2024
|
|||
| Novartis Pharma AG | 5.4% | ||||
| Novartis AG | 5.4% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.